Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Research & Development (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Research & Development for 4 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 93.34% year-over-year to $2.9 million, compared with a TTM value of $66.4 million through Sep 2025, down 61.48%, and an annual FY2024 reading of $151.5 million, down 32.61% over the prior year.
  • Research & Development was $2.9 million for Q3 2025 at Atara Biotherapeutics, down from $7.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $75.0 million in Q1 2022 and bottomed at $2.9 million in Q3 2025.
  • Average Research & Development over 4 years is $45.8 million, with a median of $49.6 million recorded in 2023.
  • The sharpest move saw Research & Development dropped 13.49% in 2023, then plummeted 93.34% in 2025.
  • Year by year, Research & Development stood at $62.5 million in 2022, then fell by 20.66% to $49.6 million in 2023, then tumbled by 42.09% to $28.7 million in 2024, then crashed by 89.82% to $2.9 million in 2025.
  • Business Quant data shows Research & Development for ATRA at $2.9 million in Q3 2025, $7.3 million in Q2 2025, and $27.4 million in Q1 2025.